Navigation Links
Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
Date:5/21/2008

mmon malignancy found in women. Cervical cancer is caused by "high-risk" types of the human papillomavirus (HPV), which are sexually transmitted. It's estimated that 80 percent of women will get an HPV infection at some point in their lives. However, in most cases, the infection goes away or is suppressed by the body without causing problems. It is only infections that persist that can cause abnormal cells to form that may develop into cervical cancer if not detected and treated early. One report from the World Health Organization estimates that only about 5 percent of women had been screened for cervical disease in the previous five years, compared to 40-50 percent in the developed world.

About QIAGEN (http://www.qiagen.com)

QIAGEN NV, headquartered in the Netherlands, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue, and assays make these isolated molecules visible to facilitate such vital activities as biological research and detection of disease. QIAGEN has developed and markets more than 500 products as well as instruments that make their use more efficient and accurate. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide, including the only FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than 2,600 people in over 30 locations worldwide.

Pam Rasmussen Dr. Thomas Theuringer

QIAGEN Gaithersburg QIAGEN GmbH

+1-240-686-7616 +49-
'/>"/>

SOURCE Qiagen N V
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
2. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
3. Annual FIT Testing Detects Colorectal Cancer Two Years Earlier Than Colonoscopy Alone, Study of High-Risk Population Finds
4. Study Analyzed SYMBICORT(R) in Children with Persistent Asthma
5. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
6. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
7. Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
8. Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma
9. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
10. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
11. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)...   Decision Resources Group finds that ... frequent dosing as the highest unmet need in ... on both patients and providers associated with monthly ... which are the current standard of care. The ... in development for dosing every two to three ...
(Date:7/2/2015)... , July 2, 2015  Konica Minolta, Inc. (Konica ... that it has acquired Sawae Technologica Ltda., an X-ray ... Brazil , through its Brazilian healthcare sales company, ... Local Brazil market ... increasing population exceeding 200 million, significant healthcare technical advancements ...
(Date:7/2/2015)... Ill. , July 2, 2015  AbbVie (NYSE: ... results on Friday, July 24, 2015, before the market ... of the earnings conference call at 8 a.m. Central ... AbbVie,s Investor Relations website at www.abbvieinvestor.com . An ... 11 a.m. Central time. About AbbVie ...
Breaking Medicine Technology:Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 2Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 3
... Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced ... NBI-98854 in 37 tardive dyskinesia patients. For the final analysis, ... and incorrect application of the efficacy assessment protocol. With this ... dyskinesia symptoms at end of two weeks of active treatment ...
... treatment may target hunger at its source, another uses ... stomach and suppress hunger and a third explores the ... Initial results from all these studies were reported at ... in San Francisco, Calif. (Logo: ...
Cached Medicine Technology:Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 2Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 3Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 4Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 5Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 6Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 7No Pain, No Gain: Weight Loss, Disc Disease Interventional Radiology Treatments Coming 2No Pain, No Gain: Weight Loss, Disc Disease Interventional Radiology Treatments Coming 3No Pain, No Gain: Weight Loss, Disc Disease Interventional Radiology Treatments Coming 4No Pain, No Gain: Weight Loss, Disc Disease Interventional Radiology Treatments Coming 5No Pain, No Gain: Weight Loss, Disc Disease Interventional Radiology Treatments Coming 6
(Date:7/5/2015)... ... July 05, 2015 , ... Doctors at the Swedish Cancer Institute in ... one day change the outlook for people with pleural mesothelioma. Surviving Mesothelioma has just ... Researchers report that five mesothelioma patients treated with 25Gy of radiation over five days ...
(Date:7/4/2015)... (PRWEB) , ... July 04, 2015 , ... ... the solar industry’s leading recognition of technical sales expertise from the North American ... Technical Sales ProfessionalTM. NABCEP is the most highly respected and well established national ...
(Date:7/3/2015)... ... 03, 2015 , ... Scientists at several top US cancer centers believe they ... exposure. Click here to read the complete story , just posted on the ... Sinai Medical Center, and New York University exposed mice with a mutation on the ...
(Date:7/3/2015)... ... 2015 , ... Smoothies are all the rage right now and all you ... ingredients. Aurora Natural is proud to introduce a new line of all natural products ... vitamins and minerals! , Aurora is offering a variety of blends and stand-alone items ...
(Date:7/3/2015)... ... July 03, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... says will reveal biblical truth and expose popular lies regarding proper relationships according to ... Have Sex”, immediately goes into the core of the subject by explaining why certain ...
Breaking Medicine News(10 mins):Health News:New Mesothelioma Study Calls IMRT/Surgery Combo “Innovative and Promising”, According to Surviving Mesothelioma 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2
... Health researchers have received nearly $13 million from the ... for victims of terrorist attacks, wartime use of toxic ... in these studies will be ,mustard gas, (sulfur mustard) ... is that they are designed to provide rescue treatments," ...
... -- In findings with major implications for the genetics of ... Center (BIDMC) and two other science teams in New York ... networks and showed how it may work to drive cancer ... 14 in the journal Cell describe aspects of ...
... times could cause men to seek more sexual partners, giving ... Gillath, a social psychology professor at the University of Kansas. ... when faced with a threatening environment, according to sexual selection ... think about their own death, which mimics conditions of "low ...
... a five year project with a $2 million ceiling ... the SILCS diaphragm, the one-size-fits-most contraceptive barrier, combined ... to prevent the acquisition of HIV and Herpes Simplex ... and acceptable, this combination of products would provide women ...
... (HealthDay News) -- Materialistic couples may have more money, ... a new study. Researchers have found that ... on couples, happiness and stability. In conducting the ... completed by more than 1,700 married couples across the ...
... have new avenues for scientific interaction, following a cooperation ... the government of Singapore. The agreement will allow Singapore ... It also means that EMBO workshops and lectures can ... agreement of its kind between EMBO, EMBC and Singapore. ...
Cached Medicine News:Health News:National Jewish Health researchers awarded $13 million to evaluate treatments for toxic gases 2Health News:Researchers discover hidden genetic influence on cancer 2Health News:Researchers discover hidden genetic influence on cancer 3Health News:Researchers discover hidden genetic influence on cancer 4Health News:Researchers discover hidden genetic influence on cancer 5Health News:Permanently dismal economy could prompt men to seek more sex partners 2Health News:USAID awards cooperative agreement to CONRAD for multipurpose prevention study 2Health News:Couples Can Pay a Price for Materialism 2Health News:Scientists in Singapore and Europe to collaborate 2
Double-ended. Blunt and semi sharp 5 mm tips. Designated most popular model or size....
Double-ended. Designated most popular model or size....
Designated most popular model or size. Double-ended. 2 mm wide....
Desmarres Retractor Size 4...
Medicine Products: